Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study

Show other versions (1)

Bibliographic Details
Main Authors:	Catto, J, Robinson, M, Albertsen, P, Goepel, JR, Abbod, M, Linkens, D, Davis, M, Rosario, D, Warren, A, Varma, M, Griffiths, D, Grigor, K, Mayer, N, Oxley, J, Deshmukh, N, Lane, J, Metcalfe, C, Donovan, J, Neal, D, Hamdy, F
Format:	Journal article
Published:	2011

Similar Items

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.
by: Catto, J, et al.
Published: (2011)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
by: Rosario, D, et al.
Published: (2008)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
by: Lane, J, et al.
Published: (2004)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: The ProtecT three-arm RCT
by: Hamdy, FC, et al.
Published: (2020)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
by: Collin, S, et al.
Published: (2009)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
by: Burton, A, et al.
Published: (2013)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
by: Hamdy, F, et al.
Published: (2006)

Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.
by: Zuccolo, L, et al.
Published: (2013)

Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study
by: Dimitropoulou, P, et al.
Published: (2011)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.
by: Dimitropoulou, P, et al.
Published: (2011)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
by: Rosario, D, et al.
Published: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
by: Rosario, D, et al.
Published: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
by: Rosario, D, et al.
Published: (2012)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
by: Wade, J, et al.
Published: (2015)

Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protecT randomised controlled trial according to treatment received
by: Neal, D, et al.
Published: (2019)

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).
by: Mills, N, et al.
Published: (2006)

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
by: J. Donovan, et al.
Published: (2003-01-01)

The ProtecT trial: Analysis of the patient cohort, baseline risk stratification and disease progression
by: Young, GJ, et al.
Published: (2020)

Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study.
by: Mills, N, et al.
Published: (2003)

Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
by: Murad, A, et al.
Published: (2011)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
by: Lane, J, et al.
Published: (2010)

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
by: S. Sanghera, et al.
Published: (2020-10-01)

Comparative study of intelligent models for the prediction of bladder cancer progression.
by: Abbod, M, et al.
Published: (2006)

Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression.
by: Catto, J, et al.
Published: (2006)

Predictive modeling in cancer: where systems biology meets the stock market.
by: Abbod, M, et al.
Published: (2009)

Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial
by: Johnston, T, et al.
Published: (2016)

Experiences and decision processes during PSA testing and prostate biopsy: A qualitative study
by: Avery, K, et al.
Published: (2007)

Artificial intelligence for the prediction bladder cancer
by: Abbod, M, et al.
Published: (2004)

ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING
by: Burton, A, et al.
Published: (2011)

Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
by: Catto, J, et al.
Published: (2009)

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
by: Donovan, J, et al.
Published: (2003)

THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS OF TREATMENTS FOR CLINICALLY LOCALISED PROSTATE CANCER
by: Lane, J, et al.
Published: (2009)

The protect trial - Evaluating the effectiveness of treatments for clinically localised prostate cancer and associated molecular and genetic epidemiology studies
by: Lane, J, et al.
Published: (2007)

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
by: Lane, A, et al.
Published: (2016)

Development of a prognostic marker panel in bladder cancer using aberrant promoter methylation
by: Catto, J, et al.
Published: (2007)

Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks.
by: Catto, J, et al.
Published: (2003)

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial.
by: Er, V, et al.
Published: (2017)

Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
by: Avery, K, et al.
Published: (2008)

Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring.
by: Burton, A, et al.
Published: (2012)

Application of artificial intelligence to the management of urological cancer
by: Abbod, MF, et al.
Published: (2007)